Actively Recruiting
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2024-09-27
336
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
CONDITIONS
Official Title
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Expected survival period longer than 3 months
- ECOG performance status 2 or less
- Diagnosed with invasive breast cancer by histopathology
- Planning to receive TAC, TC, or TCbH chemotherapy
- Good hematology, liver, lung, and kidney function
- Signed informed consent
You will not qualify if you...
- Known allergy to rhG-CSF or PEG-rhG-CSF
- Pregnant or breastfeeding female patients
- Previous malignant tumors not cured
- Received chemotherapy or radiotherapy within 4 weeks before screening
- Received PEG-rhG-CSF within 6 weeks before screening
- Uncontrolled infectious diseases within 2 weeks before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
Research Team
M
Mengli Zhu, Master
CONTACT
W
Wangwang Zhi, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here